LaManca 1993.

Methods	Design: randomised controlled trial Randomisation: individual Trial: daily oral iron versus placebo Date of study: not stated
Participants	Setting: athletics clubs in Florida, USA Malaria endemicity: not stated Included: healthy women aged 18 years to 35 years (mean age 28 years) with ferritin < 20 ng/mL Excluded: not stated Dropouts: none reported Sample size: total: 20; intervention: 10, control: 10
Interventions	Intervention: 100 mg elemental iron daily Control: placebo Duration: 8 weeks
Outcomes	Iron indices, haemoglobin, hematocrit, exercise performance
Notes	Compliance: iron 82% of tablets taken, placebo 85% of tablets taken Conflicts of interest: not stated Funded by: FSU President's Club fund and Sigma Xi. Tablets provided by SmithKline Laboratories
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not reported
Allocation concealment (selection bias)	Unclear risk	Not reported
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Placebo administered
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported. Assessment of exercise outcomes may be influenced by knowledge of allocation
Incomplete outcome data (attrition bias) All outcomes	Low risk	No loss to follow‐up
Selective reporting (reporting bias)	Unclear risk	Not evident
Other bias	Low risk	Not evident